Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F22%3AN0000044" target="_blank" >RIV/00064190:_____/22:N0000044 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10447805 RIV/00064190:_____/23:10000982

Výsledek na webu

<a href="https://doi.org/10.1111/all.15513" target="_blank" >https://doi.org/10.1111/all.15513</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/all.15513" target="_blank" >10.1111/all.15513</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma

Popis výsledku v původním jazyce

Asthma is a heterogeneous disease, as reflected by differences in age of onset, severity, treatment response and inflammatory profile. Matrix metalloprotease (MMP)-12 has been associated with inflammation in various subtypes of asthma.1 In allergic asthma, MMP-12 activity has been implicated in the accumulation of neutrophils and eosinophils, in regulating macrophage functions and in the development of airway hyperresponsiveness (AHR).1 To date, the underlying mechanisms by which MMP-12 may drive asthma pathophysiology have not been defined, nor has inhibition of MMP-12 as a targeted therapy for asthma been assessed in humans. FP-025 is a novel, potent, and highly selective non-hydroxamate inhibitor of MMP-12 with 90-fold selectivity over the closest family member (MMP-2) and two to three orders of magnitude over the seven other MMP family members.

Název v anglickém jazyce

Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma

Popis výsledku anglicky

Asthma is a heterogeneous disease, as reflected by differences in age of onset, severity, treatment response and inflammatory profile. Matrix metalloprotease (MMP)-12 has been associated with inflammation in various subtypes of asthma.1 In allergic asthma, MMP-12 activity has been implicated in the accumulation of neutrophils and eosinophils, in regulating macrophage functions and in the development of airway hyperresponsiveness (AHR).1 To date, the underlying mechanisms by which MMP-12 may drive asthma pathophysiology have not been defined, nor has inhibition of MMP-12 as a targeted therapy for asthma been assessed in humans. FP-025 is a novel, potent, and highly selective non-hydroxamate inhibitor of MMP-12 with 90-fold selectivity over the closest family member (MMP-2) and two to three orders of magnitude over the seven other MMP family members.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30225 - Allergy

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ALLERGY

ISSN

0105-4538

e-ISSN

1398-9995

Svazek periodika

78

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

559-562

Kód UT WoS článku

000854878600001

EID výsledku v databázi Scopus

2-s2.0-85138154475